156:
233:’ (FBDD). Its proprietary drug discovery platform, Pyramid, can effectively identify novel small molecule drugs for key disease targets. Originally funded by venture capital, from a number of investors including Abingworth, Advent international, Oxford Bioscience Partners, Apax Partners and Gimv. Astex established strategic partnerships with major pharmaceutical companies including
502:
Repasky, M. P.; Murphy, R. B.; Banks, J. L.; Greenwood, J. R.; Tubert-Brohman, I; Bhat, S; Friesner, R. A. (2012). "Docking performance of the glide program as evaluated on the Astex and DUD datasets: A complete set of glide SP results and selected results for a new scoring function integrating Water
296:
fragments of drugs binding into the disease target of interest. Astex uses its knowledge of the 3-dimensional structure of the binding interaction between the compound and the target to design and grow from the initial fragment, adding further functionality to improve the binding interaction so that
252:
In 2005, the
Company changed its name to Astex Therapeutics Limited when its first product entered clinical development. In 2011, Astex Therapeutics Limited and SuperGen, Inc. (US) merged. Following the acquisition, SuperGen, Inc. changed its name to Astex Pharmaceuticals, Inc., and began trading
837:
781:
558:
Novikov, F. N.; Stroylov, V. S.; Zeifman, A. A.; Stroganov, O. V.; Kulkov, V; Chilov, G. G. (2012). "Lead Finder docking and virtual screening evaluation with Astex and DUD test sets".
288:
Astex’s
Pyramid platform assists with the rational design of novel small molecule targeted therapies. These therapies are based on the use of biophysical techniques, principally
914:
729:
327:
Several compounds from drug discovery collaborations with Astex have been advanced by Astex’s biopharma partners into clinical trials and onto the market, including
863:
958:
963:
755:
356:
968:
445:
Williams, P. A.; Cosme, J; Vinkovic, D. M.; Ward, A; Angove, H. C.; Day, P. J.; Vonrhein, C; Tickle, I. J.; Jhoti, H (2004).
390:
261:
in
October 2013 for around USD $ 900 million, and now operate as part of the Otsuka group as wholly-owned subsidiaries.
838:"Astex Pharmaceuticals and Taiho Pharmaceutical sign cancer drug deal with Merck that could be worth $ 2.5 billion"
973:
889:
782:"SuperGen, Inc. Changes Name to Astex Pharmaceuticals, Inc., Announces New Stock Ticker Symbol and New Website"
691:
Carr, R. A.; Congreve, M; Murray, C. W.; Rees, D. C. (2005). "Fragment-based lead discovery: Leads by design".
297:
the final drug compound interacts optimally with the disease target – either through inhibition or activation.
230:
368:
113:
324:
Astex has a pipeline of investigational compounds currently in various stages of clinical development.
336:
332:
155:
652:"Astex, Structural Genomix, and Syrrx. I can see clearly now: Structural biology and drug discovery"
123:
360:
308:
entered into a new partnership with Merck & Co., Inc., Kenilworth, New Jersey, USA (known as
242:
117:
278:
191:
66:
410:
Congreve, M; Murray, C. W.; Blundell, T. L. (2005). "Structural biology and drug discovery".
289:
258:
214:
149:
17:
567:
516:
458:
364:
344:
8:
571:
520:
462:
313:
301:
591:
540:
484:
312:
outside the USA and Canada) through a subsidiary, and this partnership was extended in
270:
704:
668:
651:
447:"Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone"
423:
708:
673:
632:
583:
532:
476:
427:
915:"FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma"
595:
544:
488:
285:
and then developing a targeted therapy which can arrest or reverse its progression.
807:
700:
663:
627:
622:
610:
575:
524:
466:
419:
213:
Astex is part of the Otsuka group of companies and is a wholly-owned subsidiary of
394:
246:
398:
387:
343:, subsequent to an original collaboration on FGFR inhibitors between Astex and
293:
281:
disorders. This approach involves first understanding the molecular basis of a
144:
579:
528:
952:
348:
229:, UK, to pioneer a novel approach to small molecule drug discovery known as ‘
183:
49:
471:
446:
712:
677:
636:
587:
536:
480:
431:
203:
195:
109:
347:, that was granted approval in the US and EU in 2017 for the treatment of
352:
234:
199:
328:
41:
305:
226:
207:
95:
730:"Japan's Otsuka to buy Astex Pharma for about $ 900 million: Nikkei"
611:"Fragmentary solutions. Astex therapeutics puts the pieces together"
340:
274:
238:
187:
136:
864:"Astex and Taiho strike further oncology licensing deal with MSD"
282:
557:
254:
55:
186:
company focused on the discovery and development of drugs in
257:. The combined Astex entities were subsequently acquired by
501:
225:
Astex was founded as “Astex
Technology Limited” in 1999 in
444:
367:), and received FDA market approval for the treatment of
690:
409:
309:
943:
168:
950:
756:"SuperGen to Merge with Astex for $ 25M in Cash"
94:European Corporate and Research headquarters in
890:"FDA Approves Kisqali for Breast Cancer Subset"
808:"Fragment-based approaches to drug discovery"
264:
560:Journal of Computer-Aided Molecular Design
509:Journal of Computer-Aided Molecular Design
154:
887:
667:
626:
470:
292:, to screen and identify very small, low
861:
835:
649:
217:Co. Ltd, headquartered in Tokyo, Japan.
959:Companies formerly listed on the Nasdaq
608:
14:
951:
888:Broderick, Jason M (14 March 2017).
724:
722:
319:
964:Pharmaceutical companies of England
359:inhibitor that was discovered with
194:. Astex was founded in 1999 by Sir
24:
937:
862:Brackley, Paul (21 January 2021).
25:
985:
919:U.S. Food and Drug Administration
836:Brackley, Paul (9 January 2020).
719:
339:discovered in collaboration with
98:, UK (Astex Therapeutics Limited)
253:under the ticker symbol ASTX on
907:
881:
855:
829:
800:
774:
748:
369:metastatic urothelial carcinoma
969:1999 establishments in England
684:
643:
628:10.1016/j.chembiol.2006.08.003
602:
551:
495:
438:
403:
381:
355:(brand name “Balversa”) is an
306:Taiho Pharmaceutical Co., Ltd.
13:
1:
944:Astex Pharmaceuticals website
705:10.1016/S1359-6446(05)03511-7
669:10.1016/s1074-5521(03)00030-9
424:10.1016/S1359-6446(05)03484-7
374:
231:fragment-based drug discovery
126:, Astex Therapeutics Limited)
7:
78:; 25 years ago
10:
990:
331:(brand name “Kisqali”), a
220:
580:10.1007/s10822-012-9549-y
529:10.1007/s10822-012-9575-9
163:
143:
131:
103:
90:
72:
62:
47:
37:
760:Genetic Engineering News
393:January 1, 2015, at the
265:Research and development
124:Chief Scientific Officer
656:Chemistry & Biology
615:Chemistry & Biology
472:10.1126/science.1099736
361:Janssen Pharmaceuticals
243:Janssen Pharmaceuticals
388:Tom Blundell: Director
279:central nervous system
192:central nervous system
27:Pharmaceutical company
974:Otsuka Pharmaceutical
868:Cambridge Independent
842:Cambridge Independent
365:Johnson & Johnson
290:X-ray crystallography
259:Otsuka Pharmaceutical
215:Otsuka Pharmaceutical
180:Astex Pharmaceuticals
150:Otsuka Pharmaceutical
33:Astex Pharmaceuticals
693:Drug Discovery Today
650:Mountain, V (2003).
412:Drug Discovery Today
345:Newcastle University
269:Astex is focused on
206:, and is located in
190:and diseases of the
788:. 12 September 2011
609:Wolfson, W (2006).
572:2012JCAMD..26..725N
521:2012JCAMD..26..787R
463:2004Sci...305..683W
34:
736:. 4 September 2013
271:precision medicine
32:
363:(a subsidiary of
320:Clinical pipeline
177:
176:
139:and CNS disorders
135:Therapeutics for
16:(Redirected from
981:
931:
930:
928:
926:
911:
905:
904:
902:
900:
885:
879:
878:
876:
874:
859:
853:
852:
850:
848:
833:
827:
826:
824:
822:
812:
804:
798:
797:
795:
793:
778:
772:
771:
769:
767:
752:
746:
745:
743:
741:
726:
717:
716:
688:
682:
681:
671:
647:
641:
640:
630:
606:
600:
599:
555:
549:
548:
499:
493:
492:
474:
442:
436:
435:
407:
401:
385:
294:molecular weight
173:
170:
159:
158:
86:
84:
79:
35:
31:
21:
989:
988:
984:
983:
982:
980:
979:
978:
949:
948:
940:
938:Further reading
935:
934:
924:
922:
921:. 12 April 2019
913:
912:
908:
898:
896:
886:
882:
872:
870:
860:
856:
846:
844:
834:
830:
820:
818:
810:
806:
805:
801:
791:
789:
780:
779:
775:
765:
763:
754:
753:
749:
739:
737:
728:
727:
720:
689:
685:
648:
644:
607:
603:
556:
552:
500:
496:
457:(5684): 683–6.
443:
439:
418:(13): 895–907.
408:
404:
395:Wayback Machine
386:
382:
377:
322:
267:
247:GlaxoSmithKline
223:
167:
153:
127:
121:
106:
99:
82:
80:
77:
67:Pharmaceuticals
52:
28:
23:
22:
15:
12:
11:
5:
987:
977:
976:
971:
966:
961:
947:
946:
939:
936:
933:
932:
906:
880:
854:
828:
799:
773:
762:. 7 April 2011
747:
718:
699:(14): 987–92.
683:
642:
621:(8): 799–801.
601:
550:
494:
437:
402:
399:OpenCorporates
379:
378:
376:
373:
337:CDK6 inhibitor
321:
318:
266:
263:
222:
219:
175:
174:
165:
161:
160:
147:
141:
140:
133:
129:
128:
107:
104:
101:
100:
92:
88:
87:
74:
70:
69:
64:
60:
59:
53:
48:
45:
44:
39:
26:
9:
6:
4:
3:
2:
986:
975:
972:
970:
967:
965:
962:
960:
957:
956:
954:
945:
942:
941:
920:
916:
910:
895:
891:
884:
869:
865:
858:
843:
839:
832:
816:
809:
803:
787:
783:
777:
761:
757:
751:
735:
731:
725:
723:
714:
710:
706:
702:
698:
694:
687:
679:
675:
670:
665:
661:
657:
653:
646:
638:
634:
629:
624:
620:
616:
612:
605:
597:
593:
589:
585:
581:
577:
573:
569:
566:(6): 725–35.
565:
561:
554:
546:
542:
538:
534:
530:
526:
522:
518:
515:(6): 787–99.
514:
510:
506:
498:
490:
486:
482:
478:
473:
468:
464:
460:
456:
452:
448:
441:
433:
429:
425:
421:
417:
413:
406:
400:
396:
392:
389:
384:
380:
372:
370:
366:
362:
358:
354:
350:
349:breast cancer
346:
342:
338:
334:
330:
325:
317:
315:
311:
307:
303:
298:
295:
291:
286:
284:
280:
276:
272:
262:
260:
256:
250:
248:
244:
240:
236:
232:
228:
218:
216:
211:
209:
205:
201:
197:
193:
189:
185:
184:biotechnology
181:
172:
166:
162:
157:
151:
148:
146:
142:
138:
134:
130:
125:
119:
115:
111:
108:
102:
97:
93:
89:
75:
71:
68:
65:
61:
57:
54:
51:
46:
43:
40:
36:
30:
19:
923:. Retrieved
918:
909:
897:. Retrieved
893:
883:
871:. Retrieved
867:
857:
845:. Retrieved
841:
831:
819:. Retrieved
814:
802:
790:. Retrieved
786:BusinessWire
785:
776:
764:. Retrieved
759:
750:
738:. Retrieved
733:
696:
692:
686:
659:
655:
645:
618:
614:
604:
563:
559:
553:
512:
508:
507:and glide".
504:
497:
454:
450:
440:
415:
411:
405:
383:
326:
323:
304:, Astex and
299:
287:
268:
251:
224:
212:
204:Harren Jhoti
196:Tom Blundell
179:
178:
122:David Rees (
110:Harren Jhoti
91:Headquarters
38:Company type
29:
817:. June 2006
662:(2): 95–8.
353:Erdafitinib
235:AstraZeneca
210:, England.
200:Chris Abell
58:: ASTX
953:Categories
894:Cure Today
375:References
329:ribociclib
105:Key people
42:Subsidiary
371:in 2019.
227:Cambridge
208:Cambridge
114:president
96:Cambridge
50:Traded as
925:14 April
899:25 March
873:25 March
847:25 March
821:25 March
792:14 April
766:14 April
740:14 April
713:16023057
678:12618177
637:16931326
596:22123557
588:22569592
545:34803972
537:22576241
489:23149841
481:15256616
432:15993809
391:Archived
341:Novartis
275:oncology
239:Novartis
188:oncology
137:oncology
132:Products
63:Industry
734:Reuters
568:Bibcode
517:Bibcode
459:Bibcode
451:Science
283:disease
221:History
164:Website
81: (
73:Founded
711:
676:
635:
594:
586:
543:
535:
487:
479:
430:
255:NASDAQ
202:&
152:
145:Parent
56:Nasdaq
811:(PDF)
592:S2CID
541:S2CID
485:S2CID
182:is a
18:Astex
927:2021
901:2021
875:2021
849:2021
823:2021
794:2021
768:2021
742:2021
709:PMID
674:PMID
633:PMID
584:PMID
533:PMID
477:PMID
428:PMID
357:FGFR
333:CDK4
314:2021
302:2020
277:and
273:for
245:and
171:.com
169:astx
116:and
83:1999
76:1999
815:Sp2
701:doi
664:doi
623:doi
576:doi
525:doi
505:Map
467:doi
455:305
420:doi
397:on
310:MSD
300:In
118:CEO
955::
917:.
892:.
866:.
840:.
813:.
784:.
758:.
732:.
721:^
707:.
697:10
695:.
672:.
660:10
658:.
654:.
631:.
619:13
617:.
613:.
590:.
582:.
574:.
564:26
562:.
539:.
531:.
523:.
513:26
511:.
483:.
475:.
465:.
453:.
449:.
426:.
416:10
414:.
351:.
316:.
249:.
241:,
237:,
198:,
929:.
903:.
877:.
851:.
825:.
796:.
770:.
744:.
715:.
703::
680:.
666::
639:.
625::
598:.
578::
570::
547:.
527::
519::
491:.
469::
461::
434:.
422::
335:/
120:)
112:(
85:)
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
